Marzia Cavalli

Marzia Cavalli

Auto-generated profile, based on publicly available information

Marzia Cavalli

Haematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2017 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MCMarzia Cavalli
Marzia Cavalli
LNLucia Anna De Novi
Lucia Anna De Novi
ISIrene Della Starza
Irene Della Starza
LCLuca Vincenzo Cappelli
Luca Vincenzo Cappelli
VNVittorio Nunes
Vittorio Nunes
RFRobin Foà
Robin Foà

3 May 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
ISIrene Della Starza
Irene Della Starza
LNLucia Anna De Novi
Lucia Anna De Novi
ASAlessandra Santoro
Alessandra Santoro
DSDomenico Salemi
Domenico Salemi
WTWayne Tam
Wayne Tam
AGAnna Guarini
Anna Guarini
(2019). Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. Leukemia & Lymphoma. Ahead of Print.

5 August 2019 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
APALESSANDRO PULSONI
ALESSANDRO PULSONI
ISIrene Della Starza
Irene Della Starza
LCLuca Vincenzo Cappelli
Luca Vincenzo Cappelli
MTMaria E. Tosti
Maria E. Tosti
GAGiorgia Annechini
Giorgia Annechini
RFRobin Foà
Robin Foà
Summary: Since 2000, we have investigated 67 consecutive patients with stage I/II follicular lymphoma (FL) for the presence of BCL2/IGH rearrangements by polymerase chain reaction (PCR), real time quantitative PCR (RQ‐PCR) and digital droplet PCR (ddPCR). All patients were treated with involved‐field radiotherapy (IF‐RT) (24–30 Gy). From 2005, patients with minimal residual disease (MRD) after IF‐RT received rituximab (R) (375 mg/m2, 4 weekly administrations). The median follow‐up is 82 months (17–196). At diagnosis, 72% of patients were BCL2/IGH+. Progression‐free survival (PFS) was significantly better in patients with undetectable/low levels (<10−5) of circulating BCL2/IGH+ cells at diagnosis and in those who were persistently MRD− during follow‐up (P = 0·0038). IF‐RT induced an MRD− status in 50% of cases; 16/19 (84%) MRD+ patients after IF‐RT became MRD− after R treatment. A significantly longer PFS was observed in MRD+ patients treated with R compared to untreated MRD+ patients (P = 0·049). In early stage FL, both circulating levels of BCL2/IGH+ cells at diagnosis and MRD status during follow‐up bear prognostic implications. Standard IF‐RT fails to induce an MRD‐negative status in half of patients. Most patients become MRD− following treatment with R and this is associated with a significantly better PFS.

4 December 2017 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
EGElisa Genuardi
Elisa Genuardi
DBD. Barbero
D. Barbero
IDI. Dogliotti
I. Dogliotti
BMB. Mantoan
B. Mantoan
Daniela DrandiDaniela Drandi
Daniela Drandi
FNFondazione Italiana Linfomi (Fil) Mrd Network
Fondazione Italiana Linfomi (Fil) Mrd Network